Supplements for mirtazapine weight gain: evidence review

Short answer

If you landed here because the scale moved ten pounds in two months on mirtazapine and you are looking for a supplement that will offset it — this is the article where we tell you the plain version first. No randomized trials have tested supplements specifically for mirtazapine-induced weight gain, so every recommendation below relies on indirect evidence. That does not automatically mean the supplements are ineffective; it means they have not been tested in this specific population. What exists is meta-analyses on berberine, green tea catechins, psyllium, and chromium for weight loss in general populations, plus a body of evidence on inositol that does not apply to this scenario at all.

What we are not going to do: pretend a “natural stack” can override a histamine H1 receptor block in your hypothalamus. Mirtazapine causes weight gain primarily through potent H1 antagonism (the same mechanism that makes it sedating) and no supplement unsedates your histamine receptors. What we are going to do: walk through what was actually studied, in whom, with what dose, and what the effect size was, so you can decide whether trying a supplement is reasonable for your specific case, or whether you should skip the supplement aisle and go straight to your prescriber.

The realistic promise is narrow. No randomized trials have tested supplements specifically for mirtazapine-induced weight gain, so every recommendation below relies on indirect evidence. What the existing literature does give us is a handful of meta-analyses on berberine, green tea catechins, psyllium, and chromium for weight loss in general populations, plus a body of evidence on inositol that does not apply to this scenario at all.

What we are not going to do: pretend a “natural stack” can override a histamine H1 receptor block in your hypothalamus. Mirtazapine causes weight gain primarily through potent H1 antagonism (the same mechanism that makes it sedating) and no supplement unsedates your histamine receptors. What we are going to do: walk through what was actually studied, in whom, with what dose, and what the effect size was, so you can decide whether trying a supplement is reasonable for your specific case, or whether you should skip the supplement aisle and go straight to your prescriber.

The realistic promise is narrow. Psyllium and other viscous soluble fibers have the most mechanistically coherent fit: mirtazapine drives appetite up through H1, and fiber before meals increases satiety and slows gastric emptying. The meta-analytic effect is modest (around 2 kg over ~5 months). Berberine has real metabolic effects and several meta-analyses showing modest weight reduction (effect sizes range from −0.88 kg to −2.07 kg depending on the analysis)[3][4] — its AMPK / insulin-sensitizing mechanism is genuine, but it addresses the metabolic side of weight rather than the H1-driven appetite signal directly. It is the right supplement for a subset with metabolic comorbidity, and an indirect fit where the gain is purely appetite-driven. Green tea catechins have a Cochrane verdict of “small, statistically non-significant, not clinically important.” Chromium picolinate produces ~1 kg weight loss that the Cochrane authors called “debatable clinical relevance” and that disappears when one influential trial is removed. Inositol has no evidence for antidepressant-induced weight gain; the trials people cite are for depression augmentation and they were negative.

The real question is not “which supplement stops mirtazapine weight gain?” It is more specific: is there a supplement worth trying while you talk to your prescribing clinician about dose, switching, or adjunct medication?

The verdict

Best evidence-backed fit: viscous soluble fiber (psyllium husk, glucomannan) taken before meals, based on the mechanistic match — mirtazapine drives appetite through H1 antagonism, and viscous fiber increases satiety and slows gastric emptying. The psyllium meta-analysis (six RCTs, n=354) found −2.1 kg over ~5 months at ~10.8 g/day before meals.[7] This is general-population weight loss, not mirtazapine-specific, but it is the supplement class whose mechanism plausibly counters the appetite side of H1-driven weight gain. It is also the safest option reviewed.

Mechanistically indirect fit: berberine. It has real biochemistry behind it (AMPK activation, insulin sensitization) and several meta-analyses showing modest weight reduction (−0.88 kg in the largest meta-analysis, up to −2.07 kg in another)[3][4] — this is the same berberine we cover in detail in our berberine vs GLP-1 guide, where the verdict is that berberine has genuine metabolic effects but is not a GLP-1 equivalent. For mirtazapine weight gain specifically, berberine’s mechanism targets metabolic handling (insulin sensitivity, glucose) rather than the H1-driven appetite increase that is the primary driver. It is the right supplement for a subset where metabolic dysregulation contributes to the gain, and an indirect fit where the gain is purely appetite-driven.

Evidence gap we cannot fill: inositol. It is routinely recommended in wellness content for “SSRI weight gain” or “antidepressant metabolic effects.” The actual trial evidence shows that inositol augmentation of SSRIs does not improve depression outcomes[9][10], and there are no trials of inositol for antidepressant-induced weight gain specifically. The inositol-and-weight literature is in polycystic ovary syndrome (PCOS), a different population and a different mechanism. Anyone recommending inositol for mirtazapine weight gain is extrapolating across conditions.

Avoid without exception: stimulant “fat burners” — synephrine (bitter orange), high-dose caffeine stacks, yohimbine, DMAA, DMHA, and any “thermogenic” marketed for weight loss. These are sympathomimetics that raise blood pressure and heart rate, lower seizure threshold, and have no meaningful weight-loss efficacy in meta-analysis[11]. They are the wrong tool for an H1-driven appetite problem, and they carry real cardiovascular and seizure risk: the latter is particularly relevant if you ever switch to or augment with bupropion, which itself lowers seizure threshold.

Evidence and options people search for

The evidence at a glance

The chart below summarizes the five supplements reviewed, ranked by mechanistic fit for the H1-driven appetite problem that causes mirtazapine weight gain. Bar length shows the meta-analytic effect size in kilograms of weight loss; the colored chip shows how directly the supplement’s mechanism addresses the appetite side rather than a downstream metabolic pathway; the right column notes the evidence robustness.

Why mirtazapine causes weight gain: the H1 block

To understand why most supplements are structurally limited here, you need a working picture of the mechanism. This is the single most important section of the article if you are trying to decide whether a supplement is worth your money.

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). It works by blocking presynaptic α2-adrenergic autoreceptors, which increases norepinephrine and serotonin release. But mirtazapine is also a potent antagonist of histamine H1 receptors in the hypothalamus, the same receptor that antihistamines like diphenhydramine (Benadryl) block, which is why both are sedating.

The H1 block is the primary driver of mirtazapine weight gain. A 2016 meta-regression reanalysis (He et al., PMID 27593622)[1] looked at antidepressant receptor affinities (H1, 5-HT2C, M3, α1A) and found that H1 affinity was the strongest predictor of antidepressant-induced weight gain (p<0.001), and that the apparent associations with 5-HT2C, M3, and α1A disappeared when H1 was included in the model. In other words, the histamine block is not a side note: it is the mechanism.

Histamine H1 receptors in the hypothalamus regulate satiety. When they are blocked, the satiety signal weakens and appetite increases. The FDA mirtazapine label reports that 17% of mirtazapine-treated patients reported increased appetite versus 2% on placebo, and 7.5% gained ≥7% of body weight versus 0% on placebo in controlled trials[2]. In the 8-week pediatric trial the effect was larger: 49% of mirtazapine-treated patients gained ≥7% of body weight versus 5.7% on placebo. A 2015 systematic review and meta-analysis of 257 randomized trials (PMID 25590213)[12] found mirtazapine associated with a mean weight gain of 1.5 kg, comparable to amitriptyline (1.8 kg) and less than olanzapine (2.4 kg), but meaningful when sustained over months.

Mirtazapine also antagonizes 5-HT2C and 5-HT3 receptors, which contribute to the metabolic effect: 5-HT2C antagonism in particular is linked to appetite and reward processing. But the H1 block is the dominant predictor, and that matters for what a supplement can and cannot do.

The implication for supplements is structural. A supplement can try to do one of three things, and only those three:

1. Increase satiety through a non-histamine pathway: viscous soluble fiber is the cleanest example. Fiber slows gastric emptying and triggers stretch and satiety hormone signaling that does not require H1.
2. Improve metabolic handling of calories: berberine and chromium work here, on insulin sensitivity and glucose metabolism. This is downstream of the appetite problem, not the appetite problem itself.
3. Mildly increase energy expenditure: green tea catechins (with caffeine) are the main studied example, with a Cochrane verdict of “small and not clinically important.”

None of these unblocks H1. None of these reduces the appetite signal at its source. This is why useful content on mirtazapine weight gain has to talk about clinical strategies (dose, switch, adjunct) alongside supplements; the clinical strategies can change the H1 exposure, the supplements cannot.

What people actually search for, and what the evidence says

The five supplements most commonly searched for mirtazapine weight gain are psyllium or glucomannan fiber, berberine, green tea extract / EGCG, chromium picolinate, and inositol. We will take each in order of mechanistic fit and evidence strength, not in order of marketing popularity, which is also the order in the chart above.

Psyllium and viscous soluble fiber: the best mechanistic fit

Why the mechanism matches

Mirtazapine increases appetite through H1 antagonism. Viscous soluble fibers (psyllium husk, glucomannan, β-glucan, alginate) form a gel in the stomach that slows gastric emptying, delays nutrient absorption, and increases perceived satiety. This is a satiety pathway that does not require histamine signaling. It is the supplement class whose mechanism most directly counters the appetite side of mirtazapine weight gain, rather than trying to fix metabolism downstream of overeating.

A 2019 systematic review of soluble fiber and satiety (Salleh et al., PMID 30621363)[6] found that viscous fibers reduced post-meal energy intake, with guar gum, β-glucan, and alginate showing the largest pooled effects. The mechanism is consistent across fibers: gel formation → delayed gastric emptying → stretch-receptor and gut-hormone satiety signaling.

What the trials show

The most relevant meta-analysis for this scenario is the 2023 psyllium review (PMC10389520)[7], which pooled six RCTs in overweight or obese adults (n=354). Psyllium dosed before meals at a mean of 10.8 g/day for a mean of 4.8 months produced:

• Body weight: −2.1 kg (95% CI −2.6 to −1.6, p<0.001)
• BMI: −0.8 kg/m² (95% CI −1.0 to −0.6, p<0.001)
• Waist circumference: −2.2 cm (95% CI −2.9 to −1.4, p<0.001)

A separate meta-analysis of glucomannan (six RCTs, n=225) found a smaller effect: −0.96 kg (95% CI −1.81 to −0.11, p=0.02), with high heterogeneity (I²=88%)[8].

Studied protocol (body weight)

In Zahra et al. (six RCTs, n=225), glucomannan produced −0.96 kg (95% CI −1.81 to −0.11) versus placebo, with high heterogeneity (I²=88%). Constituent trials typically used about 3 g/day, split into 1 g doses three times before meals, with adequate water, over 8–12 weeks; the meta-analysis did not report a pooled mean dose. Psyllium remains the better-studied viscous fiber in this guide (~10.8 g/day before meals). How a typical label compares: glucomannan trial floors.

The caveats are real:

• These are general overweight/obese populations, not people on mirtazapine. The H1-driven appetite increase may partially override fiber-induced satiety, or it may not — there is no trial to tell us.
• The psyllium meta-analysis pooled a small number of trials (six) with variable durations (2–12 months).
• Heterogeneity is high in the glucomannan analysis, meaning the effect varies a lot across trials.
• The effect (~2 kg over ~5 months) is modest. If mirtazapine is causing you to gain 0.5–1 kg per month, fiber may slow this but is unlikely to reverse it on its own.

Practical fiber take

If you want to try viscous fiber as an adjunct while continuing mirtazapine, the studied protocol is psyllium husk ~10 g/day, divided into doses taken before meals with a full glass of water, for at least 8–12 weeks before judging effect. Glucomannan has a smaller evidence base and a choking risk if taken without adequate water; the studied dosing is about 3 g/day split into 1 g doses three times daily before meals, each with a full glass of water. Psyllium is the safer and better-studied choice.

Safety: the main concern is GI: bloating, gas, and (counterintuitively) constipation if you do not drink enough water. Fiber supplements can reduce absorption of concurrently administered medications; separate fiber from your mirtazapine dose by at least 2 hours. There are no specific mirtazapine + fiber interaction concerns in the literature.

The studied ~10 g/day protocol is rare on shelf — psyllium trial floors vs typical label amounts.

Berberine: real biochemistry, modest evidence, indirect mechanism for this scenario

What the trials show

Berberine is an alkaloid that activates AMP-activated protein kinase (AMPK) and improves insulin sensitivity. It has a plausible metabolic mechanism for weight, but the meta-analytic evidence is inconsistent.

Three meta-analyses of berberine for obesity indices tell different stories:

• Ilyas 2020 (12 RCTs): body weight −2.07 kg (95% CI −3.09 to −1.05, p<0.001), BMI −0.47 kg/m², waist circumference −1.08 cm[3].
• IJO 2025 (23 RCTs): body weight −0.88 kg (95% CI −1.36 to −0.39, p=0.0003), BMI −0.48 kg/m², waist circumference −1.32 cm[4].
• Xiong 2020 dose-response (10 RCTs): body weight −0.11 kg (95% CI −0.99 to 0.76, p=0.79, not significant), BMI −0.29 kg/m² (significant), waist circumference −2.75 cm (significant)[5].

The dose-response analysis found that benefits were more pronounced at doses ≥1 g/day and with longer duration, but body weight specifically did not move significantly in that pooled estimate. Strip the marketing, keep this: berberine probably has a small effect on weight, but the size of that effect is unstable across analyses and ranges from “nothing” to “about 2 kg.”

Why it is an indirect lever for mirtazapine

Berberine acts on metabolic pathways: AMPK, insulin sensitivity, glucose handling. These are real effects, and they are the reason berberine has a place in our broader metabolic coverage (see our berberine vs GLP-1 guide). Mirtazapine weight gain, however, is primarily driven by H1-mediated appetite increase rather than by metabolic dysregulation. If your weight gain is driven by eating more because mirtazapine has weakened your satiety signal, berberine does not address the appetite side directly. It addresses a downstream metabolic consequence, and only partially.

There is a subset where berberine is more directly relevant: people on mirtazapine who have pre-existing metabolic syndrome, insulin resistance, or who are gaining weight partly through metabolic dysregulation rather than purely through increased intake. In that subset the metabolic mechanism has real relevance, and this is consistent with the berberine-vs-ozempic verdict that berberine has genuine metabolic utility, just not GLP-1-level weight loss. Berberine works for what it works for. For mirtazapine weight gain specifically, it is an indirect fit unless metabolic comorbidity is part of your picture.

Counter-evidence you should know

The Xiong 2020 dose-response meta-analysis explicitly found no significant change in body weight (WMD −0.11 kg, p=0.79)[5], even though BMI and waist circumference moved. This means that even within the berberine-favorable literature, the body-weight result is not robust. The IJO 2025 meta-analysis (the largest, 23 RCTs) found a significant but small effect (−0.88 kg)[4]. The asymmetry between “−2.07 kg” and “−0.11 kg” across meta-analyses of largely overlapping trial pools tells you the evidence base is fragile.

Practical berberine take

The studied dose range is 1000–3000 mg/day, typically divided. The dose-response analysis suggested ≥1 g/day is where effects appear. Onset is not immediate: most trials run 8–12 weeks. Berberine inhibits CYP3A4 in vitro, which means it can interact with medications metabolized by that enzyme; tell your prescriber you are taking it, particularly if you are on other medications. The practical severity with mirtazapine itself is low, and the prescriber heads-up is the point. The studied doses against the shelf: berberine trial floors.

Green tea catechins / EGCG: the Cochrane verdict is not kind

What the trials show

The most rigorous assessment of green tea for weight is the Cochrane review (Jurgens et al., CD008650)[13], which pooled 15 weight-loss trials and 3 weight-maintenance trials (1,945 participants, 12–13 weeks). The headline finding: green tea preparations produced a small, statistically non-significant weight loss that is not likely to be clinically important. Outside Japan, the pooled mean difference was −0.04 kg (95% CI −0.5 to 0.4, p=0.88). Inside Japan, individual trial effects ranged from −0.2 kg to −3.5 kg but could not be pooled due to heterogeneity.

A 2009 meta-analysis (Hursel et al., PMID via IJO 2009)[14] found a small significant effect of catechins: −1.31 kg (p<0.001), moderated by habitual caffeine intake (low-caffeine consumers got more effect) and ethnicity (Asians tended to get more effect than Caucasians, though not significantly). A 2020 dose-response meta-analysis found −1.78 kg (95% CI −2.80 to −0.75, p=0.001) for body weight, with greater waist-circumference reduction at doses ≥800 mg/day and durations <12 weeks[15].

The picture: green tea catechins probably produce a small weight effect (somewhere between “nothing” and ~1.5 kg), the effect is heavily dependent on caffeine content and population, and the Cochrane verdict is that it is not clinically important.

The caffeine problem

A meaningful part of the green tea catechin effect is actually caffeine. Caffeine increases energy expenditure modestly and may suppress appetite acutely. This is why low-caffeine consumers (who have not built tolerance) show larger effects in the Hursel meta-analysis[14]. Decaffeinated green tea extracts show smaller or absent effects.

For someone on mirtazapine, high-dose caffeine is a double-edged choice. Mirtazapine is sedating (H1 block), so people sometimes self-medicate the sedation with caffeine, but high-dose caffeine can worsen anxiety and sleep, both of which are relevant to the depression being treated. If you are considering a green tea extract for weight, the caffeine load matters: thermogenic supplements often contain 300–600 mg caffeine per serving, which is 3–6 cups of coffee equivalent. That is a stimulant dose, not a tea dose. One more low-level flag: on beta-blockers (propranolol, metoprolol, bisoprolol), high-dose caffeine and EGCG stacks can produce palpitations and blood-pressure swings, so keep your clinician in the loop and watch pulse and pressure.

Practical EGCG take

If you want to try green tea catechins, the studied range is roughly 270–800 mg/day of EGCG, typically with some caffeine. Decaffeinated extracts have weaker evidence. Onset is 8–12 weeks. The FDA has issued warnings about green tea extract and liver injury (rare but real idiosyncratic hepatotoxicity, particularly with fasting or high doses) — if you have any liver enzyme elevation or are taking other hepatotoxic medications, this is not the supplement to stack on.

Studied protocol (body weight)

In Lin et al., 2020 (Phytotherapy Research; PMID 32372444), pooled RCTs reported −1.78 kg (95% CI −2.80 to −0.75) on green tea preparations; waist reduction was greater at ≥800 mg/day and durations under 12 weeks.

Counter-evidence

The Cochrane review (Jurgens et al., CD008650, 15 weight-loss trials, n=1,945) concluded the pooled effect was small and not clinically important (−0.04 kg outside Japan, 95% CI −0.5 to 0.4). Part of any effect is caffeine, not catechins alone. How a typical label compares: green tea extract trial floors.

Chromium picolinate: small effect, not robust

What the trials show

The most rigorous assessment is the Cochrane review (Tian et al., CD010063)[16], which pooled nine RCTs (622 participants, 8–24 weeks). Across chromium picolinate doses (200–1000 µg/day), the effect on body weight was −1.1 kg (95% CI −1.7 to −0.4, p=0.001) — but the authors rated this as low-quality evidence (GRADE) and described the clinical relevance as “debatable.” No dose gradient could be established: more chromium did not produce more weight loss.

The earlier Pittler meta-analysis (PMID 12664086)[17] found the same −1.1 kg point estimate, but the sensitivity analysis is the important part: when one influential trial was removed, the effect dropped to −0.9 kg (95% CI −2.0 to 0.2) and was no longer statistically significant. The funnel plot was asymmetrical, suggesting publication bias. In plain terms: the chromium-weight result is propped up by a single trial, and without that trial it evaporates.

A 2019 meta-analysis (Tsang et al.) found a small significant decrease in weight, BMI, and body fat percentage, with the authors stating the clinical relevance for weight loss is uncertain.

Why it does not fit mirtazapine weight gain

Chromium is proposed to work through insulin signaling: it is sometimes called a “glucose tolerance factor.” The mechanism is downstream of appetite, like berberine, and there is no mirtazapine-specific trial. The effect size (~1 kg, fragile) is smaller than fiber and less robust than berberine’s better meta-analyses.

Practical chromium take

The studied dose is 200–1000 µg/day of chromium picolinate, for 12–16 weeks. Adverse events in trials were mild (watery stools, headache, urticaria). There are case reports of renal impairment with very high chronic doses. Stay within the studied range.

Studied protocol (body weight)

In the Cochrane review by Tian et al. (CD010063, PMID 24293292; nine RCTs, n=622, 8–24 weeks), chromium picolinate at 200–1000 µg/day produced −1.1 kg (95% CI −1.7 to −0.4) versus placebo: graded low-quality evidence with debatable clinical relevance, and no dose gradient (more chromium did not mean more weight loss). In Pittler 2003 (PMID 12664086), removing one influential trial dropped the pooled estimate to −0.9 kg (95% CI −2.0 to 0.2), no longer statistically significant. How a typical label compares: chromium picolinate trial floors.

Inositol: the evidence gap we keep flagging

This is the section where most mirtazapine-weight-gain content gets a fact wrong.

Inositol (myo-inositol) is routinely recommended in wellness content for “SSRI weight gain” or “antidepressant metabolic effects.” When you trace the citation chain, the trials being cited are not about antidepressant-induced weight gain at all; they are about inositol as an augmentation strategy for depression or OCD, and those trials were negative.

What the trials actually show

The relevant trials are:

• Levine 1999: double-blind RCT of inositol (12 g/day) augmentation of SSRIs in 27 depressed patients who had not responded to SSRIs alone. No greater or faster improvement with inositol plus SSRI compared to SSRI alone.[9]
• Nemets 1999: double-blind RCT of inositol (12 g/day) augmentation in 36 MDD patients who failed to respond to SSRIs. Inositol did not improve depression in SSRI treatment failures.[10]
• Fux 1999: double-blind crossover of inositol (18 g/day) augmentation of SRIs in 10 OCD patients. No significant difference between inositol and placebo phases.
• A Cochrane review of inositol for depressive disorders (CD004049) concluded that the pooled estimate of effect was consistent with both a presence and absence of benefit, and that no firm conclusion could be drawn.

None of these trials measured weight as a primary outcome. The inositol-and-weight literature that does exist is in polycystic ovary syndrome (PCOS), a different population, a different endocrine mechanism, and not transferable to mirtazapine-induced weight gain.

Why we keep flagging this

When a blog says “inositol helps with antidepressant weight gain,” the evidence being cited is either (a) a depression-augmentation trial that was negative and did not measure weight, or (b) a PCOS trial in a different population. Neither supports the claim. This is the same kind of citation drift we flagged in our SSRI-induced ED article for maca; studies get cited for purposes they were not designed to test, and the sex (or in this case the condition) of the participants does not match the recommendation.

Red flags: stimulant fat burners to avoid on mirtazapine

The supplement aisle is full of “thermogenic” and “fat burner” products marketed for weight loss. For someone on mirtazapine (or any antidepressant) most of these are the wrong tool and several are dangerous.

Synephrine (bitter orange / Citrus aurantium)

Synephrine is a sympathomimetic alkaloid that replaced ephedra after the FDA banned ephedra in 2004. It is structurally similar to ephedrine and raises blood pressure and heart rate. A 2022 systematic review and meta-analysis (Stohs et al., PMC9572433)[11] concluded that synephrine influences blood pressure and heart rate but has no significant effects on weight loss and body composition, meaning it carries cardiovascular risk without delivering the weight benefit. Cardiac adverse events associated with synephrine include hypertension, tachyarrhythmia, QT prolongation, ventricular fibrillation, myocardial infarction, and sudden death, though prevalence is unknown.

The French food safety authority (ANSES) recommends synephrine intake stay below 20 mg/day and recommends against combining synephrine with caffeine[11]. The German BfR advises that synephrine products are unsuitable for anyone with hypertension, cardiovascular illness, or who is taking blood pressure medication, thyroid medication, sympathomimetics, or monoamine oxidase inhibitors, the last of which is a class of antidepressant.

For mirtazapine specifically: mirtazapine is sedating through H1, so a stimulant feels like it “counters” the sedation, but it does not counter the appetite mechanism and it adds cardiovascular load. It is the wrong tool.

High-dose caffeine stacks

“Thermogenic” supplements often contain 300–600 mg caffeine per serving — 3–6 cups of coffee equivalent. A 2025 pharmacokinetic/pharmacodynamic review (PMC11802704)[18] found that caffeine interacts with antidepressants in drug-specific ways: fluvoxamine significantly alters caffeine pharmacokinetics, caffeine increases plasma paroxetine concentration, and high-dose caffeine with MAOIs carries significant hypertension risk (particularly with tranylcypromine). Caffeine can also worsen the anxiety and insomnia that mirtazapine is often prescribed alongside depression to address.

For someone on mirtazapine, the caffeine load in fat-burner products is a poor trade: a small, caffeine-dependent weight effect (per the green tea literature) at the cost of worsened anxiety, sleep disruption, and potential pharmacokinetic interactions.

Yohimbine, DMAA, DMHA

Yohimbine is an alpha-2 adrenergic antagonist that raises sympathetic outflow and provokes anxiety — contraindicated in anyone with anxiety, panic, or PTSD, which describes a substantial proportion of people on antidepressants. DMAA and DMHA are amphetamine analogues that appear in some aggressive “fat burner” products despite FDA warnings; they carry severe cardiovascular and psychiatric risk. None of these has mirtazapine-specific evidence and all of them add risk to an antidepressant context.

Clinical levers we do not own

This article is about supplements, but the comparison requires naming the clinical strategies that have larger effect sizes than any supplement reviewed above. These are prescription decisions made with your prescriber, not supplement decisions, and we will not recommend them, only describe them so you can have an informed conversation.

A 2015 systematic review and meta-analysis of 257 randomized trials (PMID 25590213)[12] found the following weight changes associated with relevant drugs:

• Bupropion: −1.3 kg (weight-neutral to weight-loss). Bupropion is a norepinephrine-dopamine reuptake inhibitor used for depression and (in combination with naltrexone, as Contrave) for obesity. A 24-week dose-response study showed 7.2% weight loss at 300 mg SR and 10.1% at 400 mg SR. Switching from mirtazapine to bupropion is a documented clinical strategy for patients whose weight gain is intolerable, made by a prescriber based on your depression profile.
• Topiramate: −3.8 kg. Topiramate is an anticonvulsant used off-label as an adjunct for psychotropic-induced weight gain. Meta-analyses of adjunct topiramate for psychotropic weight gain report mean losses of −2.52 to −3.95 kg. The cost is cognitive side effects (word-finding difficulty, cognitive dulling, fatigue) and rare risks (glaucoma, acidosis, oligohydrosis).
• Metformin: −1.1 kg. Metformin is the most-studied adjunct for psychotropic-induced weight gain, generally well-tolerated, and considered a first-line adjunctive choice in guidelines. Adjunct metformin meta-analyses report mean losses of −2.93 to −2.94 kg in psychotropic-weight-gain populations (mostly antipsychotic data; antidepressant-specific data is thinner).

We name these to be clear about magnitude, not to steer you toward them: the clinical adjunct options produce weight changes of ~1–4 kg in meta-analysis, which is the same range or larger than the best supplement evidence (psyllium −2.1 kg). If your weight gain is significant, the highest-leverage call is a conversation with your prescriber about whether dose adjustment, switching, or adjunct medication is appropriate for your case, not a supplement.

A note on what this article does not cover

This article does not cover the prescription strategies for mirtazapine weight gain in detail, dose reduction, switching to bupropion, adjunct metformin or topiramate, or GLP-1 receptor agonist prescription. These are documented in the medical literature and are typically more effective than any supplement. They require a prescribing clinician’s involvement, which is exactly the point.

This article also does not cover the behavioral layer (caloric awareness, protein prioritization, resistance training, sleep) which is the actual foundation of any weight management strategy and which no supplement replaces. If you are gaining weight on mirtazapine, the first intervention is to look honestly at intake (mirtazapine increases appetite, so you may be eating more without fully registering it), and the second is to talk to your prescriber. Supplements are third.

We reason in public, surface the evidence, and let readers draw their own conclusions. We do not prescribe, we do not tell readers what to do with their medications, and we do not present editorial reasoning as a substitute for individualized clinical advice.

What you should take away

For the full label-reading framework before buying any supplement mentioned below, see our supplement label guide and our third-party certification reference.

After reading this, you should be able to answer six questions for yourself.

What is actually known

• Mirtazapine weight gain is primarily H1-histamine-driven (PMID 27593622), with 7.5% of adults gaining ≥7% body weight in controlled trials and 17% reporting increased appetite.
• No supplement has a randomized trial specifically for mirtazapine-induced weight gain. All evidence below is extrapolated from general obesity trials.
• Viscous soluble fiber (psyllium ~10 g/day before meals) has the best mechanistic fit (satiety via non-histamine pathway) and a meta-analytic effect of ~−2 kg over ~5 months, modest, general-population, but the right mechanism.
• Berberine has several meta-analyses showing modest weight reduction (−0.88 to −2.07 kg) and a metabolic mechanism (AMPK, insulin sensitivity) that is an indirect fit for an H1-driven appetite problem, useful where metabolic comorbidity contributes, less direct where the gain is purely appetite-driven.
• Green tea catechins have a Cochrane verdict of “small, not clinically important,” with a caffeine-dependent effect.
• Chromium picolinate produces ~−1 kg that loses significance when one influential trial is removed; Cochrane called the clinical relevance debatable.
• Inositol has no evidence for antidepressant-induced weight gain; the cited trials are for depression augmentation (negative) or PCOS (different population).

What is still unknown

• Whether any supplement specifically counters H1-driven appetite in mirtazapine-treated patients, there is no trial.
• Whether berberine’s metabolic effect translates to mirtazapine weight gain in patients without metabolic comorbidity.
• Whether fiber-induced satiety can override H1-antagonism-driven appetite increase, or only partially blunt it.
• The interaction profile of berberine (CYP3A4 inhibition) with mirtazapine and co-prescribed medications in real-world use.

Where the evidence ends

The evidence ends at general-population obesity trials. It does not extend to mirtazapine-specific cohorts, to long-term safety of these supplements in antidepressant-treated patients, or to combinations. If you are on a specific mirtazapine dose, with specific co-medications, the evidence base for supplements in your specific case is extrapolation.

When a supplement may be a reasonable choice

• You are on mirtazapine with intolerable weight gain, your prescriber is aware, you have already discussed prescription strategies, and you want to add something with the best available mechanism: psyllium husk ~10 g/day before meals for a 12-week trial is the most mechanistically justified option.
• You have a metabolic comorbidity component (insulin resistance, metabolic syndrome) on top of the mirtazapine weight gain: berberine ≥1 g/day has a mechanistic rationale and some meta-analytic support, with the caveat that the body-weight result is not robust.
• You are willing to track outcomes honestly (weight and waist circumference weekly, intake honestly logged) over 12 weeks and stop the supplement if there is no measurable effect.

When a supplement is definitely not the right choice

• You are considering stopping mirtazapine to try a supplement instead, the supplement question is “in addition to,” not “instead of.”
• You are considering a stimulant “fat burner” (synephrine, high-dose caffeine, yohimbine, DMAA, DMHA), cardiovascular and seizure risk, no meaningful efficacy, wrong mechanism.
• You are taking inositol expecting it to counter antidepressant weight gain, the evidence does not support this use.
• You are assuming berberine or chromium will “cancel out” the H1 appetite effect: they target metabolism, not the histamine-driven appetite signal.
• Your weight gain is rapid (>1 kg/month) or large (>5 kg in 3 months), this is a prescriber conversation, not a supplement trial.

Questions to discuss with your prescribing clinician

• Whether a dose adjustment of mirtazapine might reduce weight gain while maintaining mood benefit.
• Whether switching to bupropion (weight-neutral to weight-loss) is appropriate for your depression profile.
• Whether adjunct metformin or topiramate is an option, these have larger effect sizes than any supplement reviewed here.
• Whether any supplements you are considering interact with mirtazapine or your other medications (particularly relevant for berberine and CYP3A4, or green tea extract and liver enzymes).
• Whether a combined approach (prescription optimization plus a targeted supplement trial) is reasonable for your case.

FAQ

How this article was researched

Evidence scan: PubMed and Cochrane Library, July 2026. Search terms included “mirtazapine weight gain mechanism,” “histamine H1 antidepressant weight gain,” “antidepressant receptor affinity weight gain meta-regression,” “berberine obesity meta-analysis,” “berberine weight loss randomized trial,” “green tea catechins weight loss Cochrane,” “EGCG weight meta-analysis,” “psyllium weight loss meta-analysis,” “glucomannan weight meta-analysis,” “soluble fiber satiety energy intake,” “chromium picolinate weight Cochrane,” “inositol SSRI augmentation,” “inositol depression Cochrane,” “synephrine safety meta-analysis,” “caffeine antidepressant interaction pharmacokinetics,” and “drugs associated with weight change meta-analysis.”

Each cited study was verified against PubMed by PMID or against the Cochrane Library by review identifier. The mirtazapine mechanism section is anchored to the FDA mirtazapine label (DailyMed), the StatPearls mirtazapine entry, and a 2016 meta-regression reanalysis (He et al., PMID 27593622) that established H1 affinity as the strongest predictor of antidepressant-induced weight gain.

A key distinction maintained throughout: trials in general overweight/obese populations and trials in mirtazapine-treated patients are not interchangeable. Where trials were in general populations (all the supplement meta-analyses), the article says so and does not extrapolate to mirtazapine-specific efficacy. Where trials were in PCOS for inositol, the article says so and does not extrapolate to antidepressant-induced weight gain. Where depression-augmentation trials of inositol were negative and did not measure weight, the article says so and does not cite them as weight evidence.

Counter-evidence is reported rather than omitted: the Xiong 2020 berberine dose-response meta-analysis that found no significant body-weight change is reported alongside the Ilyas 2020 meta-analysis that found −2.07 kg. The Pittler chromium sensitivity analysis that loses significance when one trial is removed is reported alongside the headline −1.1 kg. The Cochrane green tea verdict of “not clinically important” is reported rather than buried.

Research date: July 2026. Updates planned when mirtazapine-specific supplement trials publish, when new meta-analyses of berberine or fiber for weight publish, or when FDA or EMA safety communications on stimulant fat burners update.